There are a number of newer targeted biological therapies which are showing promise for the treatment of chronic myeloid leukaemia. Interferon can be used and has a reasonable response rate. Specific tyrosine kinase inhibitors can also have an excellent result. More details will follow: visitwww.vir...
Age, gender, performance status, and techniques used for T315I detection might be important prognosis factors affecting OS across different phases of CML and Ph+ ALL. Table 1. OS and PFS of CML and Ph+ ALL patients from T315I detection CML CP (N=82) CML AP (N=38) CML BP (N=56) ...
浙江大学博士学位论文CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究姓名:***学位级别:博士专业:内科学(血液病学)指导教师:**20120518浙江大学博士学位论文中文摘要CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究浙江大学医学部博士研究生导师内科学(血液病学)罗依黄河教授中文...
Patients With Additional Chromosomal Abnormalities in Chronic CML Have Worse Prognosis, SurvivalLourdes Briz
imatinib doses had higher and faster response rates in the first year of treatment, but by 42 months the high- and low-dose arms showed similar rates of major molecular response (MMR) and no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (...
The Sokal index predicts survivalbased characteristics such as the patient’s age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood. Depending on the Sokal score, patients are classified as having low-risk, intermediate-risk, or highrisk CML, ...
After the introduction of tyrosine kinase inhibitors (TKIs), the annual rate of progression from CML-CP to AP or BP dramatically decreased to 1–1.5% from more than 20% [1, 2]. However, the prognosis for adult patients with de novo or secondary CML-BP remains poor; median survival is ...
when present on their own, were predicted to confer weaker But if the mutation rate in CP CML stem cells is so impressively high, why are relapse rates in CP patients so low?100 And why potency. The clinical relevance of newly detected mutations in the are relapses in this clinical ...
likely because of their potent efficacy and the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. All four TKIs are equivalent if the aim of therapy is to improve survival. In younger patients with high‐risk disease and in wh...
Imatinib has significantly improved the prognosis of CML[3]. The International Randomized Study of Interferon and STI571 (IRIS) trial found an estimated cumulative com- plete cytogenetic response rate (CCyR) and overall survival of 87% and 89%, respectively, among 553 patients who received first...